Cancer Surveillance Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
National Cancer Registry Ireland, Cork, Ireland.
JCO Glob Oncol. 2024 Oct;10:e2400249. doi: 10.1200/GO-24-00249. Epub 2024 Oct 31.
Cancer recurrence is an important long-term outcome of cancer survivors that is often not routinely collected and recorded by population-based registries. In this study, we review population-based studies to determine the current availability, landscape, and infrastructure of long-term outcomes, particularly metastatic recurrence, in women initially diagnosed with nonmetastatic breast cancer (MBC).
We reviewed the literature to identify studies that used population-based registry data to examine the distribution of metastatic recurrence in women diagnosed with non-MBC. Data on outcomes and methods of ascertainment were extracted. Registry infrastructure including sources and funding was also reviewed.
A total of 23 studies from 11 registries in eight countries spanning Europe, North America, and Oceania were identified and included in the review. Most studies were retrospective in nature and collected recurrence data only for ad hoc studies rather than as part of their routine registration. Definition of recurrence and data sources varied considerably across studies: the cancer-free time interval between the start of follow-up and risk window ranged from the diagnosis of primary tumor (n = 7) to 6 months from diagnosis (n = 1); the start of follow-up differed between initial diagnosis (n = 16) and treatment (n = 7).
Cancer surveillance should encompass outcomes among survivors for research and monitoring. Studies are underway, but more are needed. Cancer registries should be supported to routinely collect recurrence data to allow complete evaluation of MBC as an outcome to be conducted and inform health care providers and researchers of the prognosis of both nonmetastatic and metastatic patients with breast cancer.
癌症复发是癌症幸存者的一个重要长期预后结果,但通常未被基于人群的登记处常规收集和记录。在这项研究中,我们回顾了基于人群的研究,以确定当前非转移性乳腺癌(MBC)初始诊断女性的长期结局(尤其是转移性复发)的现有可用性、情况和基础设施。
我们查阅文献,确定了使用基于人群的登记处数据来研究女性非-MBC 患者中转移性复发分布的研究。提取了结局和确定方法的数据。还审查了登记处基础设施,包括来源和资金。
从欧洲、北美和大洋洲 8 个国家的 11 个登记处确定并纳入了共 23 项研究。大多数研究的性质是回顾性的,仅为专门研究收集复发数据,而不是作为其常规登记的一部分。复发的定义和数据来源在各个研究中差异很大:从开始随访到风险窗口期之间癌症无复发的时间间隔从原发性肿瘤诊断(n = 7)到诊断后 6 个月(n = 1)不等;初始诊断(n = 16)和治疗(n = 7)之间的随访开始时间不同。
癌症监测应包括幸存者的研究和监测结果。虽然正在进行研究,但还需要更多的研究。应支持癌症登记处定期收集复发数据,以便对 MBC 作为结局进行全面评估,并为乳腺癌非转移性和转移性患者的预后提供信息,以告知医疗保健提供者和研究人员。